Physician profile
Eve Ariel Fields
NPI 1417052234
$2,363.64
in general payments reported to CMS, 2019-2025
19 companies · $577 in 2025
The $577 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.46 · 2020: $243 · 2021: $347 · 2022: $191 · 2023: $451 · 2024: $490 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $381.03 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $253.73 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.93 | 2020-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $247.87 | 2020-2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $217.92 | 2019-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $171.27 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $143.60 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $110.69 | 2021-2024 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $100.62 | 2025 | Trintellix |
| Lundbeck LLC | $96.18 | 2020-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $88.64 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $69.19 | 2020-2021 | |
| Indivior INC. | $61.91 | 2023-2024 | Perseris |
| Axsome Therapeutics, INC. | $49.41 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $46.36 | 2024-2025 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $26.60 | 2025 | |
| Celgene Corporation | $23.90 | 2025 | Cobenfy |
| Lilly USA, LLC | $14.17 | 2025 | Kisunla |
| Noven Therapeutics, LLC | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.